Advertisement

Thrombus Targeting of Plasminogen Activators and Anticoagulants

  • Karlheinz Peter
  • Christoph Bode
Chapter

Abstract

Large-scale studies with mortality endpoints comparing fibrinolytic therapy with placebo in patients with acute myocardial infarction (AMI) have documented the benefit of timely dissolution of coronary arterial thrombi by intravenous infusion of plasminogen activators (Fig. 1).(1)

Keywords

Plasminogen Activator Clot Lysis Bispecific Antibody Recombinant Fusion Protein Single Chain Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Armstrong PW, Collen D (2001) Fibrinolysis for acute myocardial infarction: Current status and new horizons for pharmacological reperfusion, Circulation 103: 2862–66Google Scholar
  2. 2.
    The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615— 1622Google Scholar
  3. 3.
    Bode C, Smalling RW. Berg O, Burnett C, Lorch O, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA. Weaver WD. for the RAPID II Investigators (1996) Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94:891–898CrossRefGoogle Scholar
  4. 4.
    Assessment of the Safety and Efficacy of a New Thrombolytic Investigators (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 354: 716–22Google Scholar
  5. 5.
    The GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 357: 1905–1914CrossRefGoogle Scholar
  6. 6.
    Hui KY, Haber E, Matsueda GR (1983) Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 222:1129— 113211.CrossRefGoogle Scholar
  7. 7.
    Califf RM (2000) Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Am Heart J 139 Suppl: S33 — S37CrossRefGoogle Scholar
  8. 8.
    Topol EJ, Byzova TV, Plow EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353: 227–31CrossRefGoogle Scholar
  9. 9.
    Smith JW, Tachias K, Madison EL (1995) Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin allbß3. J Biol Chem 270: 30486–30490CrossRefGoogle Scholar
  10. 10.
    Bode C, Matsueda GR, Hui KY, Haber E (1985) Antibody-directed urokinase: a specific fibrinolytic agent. Science 229: 765–767CrossRefGoogle Scholar
  11. 11.
    Runge MS, Bode C, Matsueda GR, Haber E (1988) Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 27: 1153–1157CrossRefGoogle Scholar
  12. 12.
    Runge MS, Bode C, Matsueda GR, Haber E (1987) Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 84: 7659–7662CrossRefGoogle Scholar
  13. 13.
    Bode C, Runge MS. Schönermark S, Eberle T, Newell JB. Kübler W. Haber E (1990) Conjugation to antifibrin Fab’ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 81:1974–1980CrossRefGoogle Scholar
  14. 14.
    Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T. Arens M. Newell JB, Kübler W. Haber E (1991) Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 84: 805–813CrossRefGoogle Scholar
  15. 15.
    Dewerchin M, Lijnen HR. Stassen JM. De Cock F, Quertermous T, Ginsberg MH, Piow EF, Collen D (1991) Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 78: 1005–1018Google Scholar
  16. 16.
    Bode C, Runge MS. Branscomb EE, Newell JB. Matsueda GR. Haber E (1989) Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator. J Biol Chem 264: 944–948Google Scholar
  17. 17.
    Ruef J, Nordt TK, Peter K, Runge MS, Kübler W, Bode C (1999) A bispecific antifibrin-antiplatelet urokinase conjugate ( BAAUC) induces enhanced clot lysis and inhibits platelet aggregation. Thromb Haemost 82: 109–114Google Scholar
  18. 18.
    Charpie JR, Runge MS, Matsueda GR, Haber E (1990) A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase. Biochemistry 29: 6374–6378CrossRefGoogle Scholar
  19. 19.
    Runge MS, Bode C, Savard CE. Matsueda GR, Haber E (1990) Antibody-directed fibrinolysis: a bispecific (Fab`)2 that binds to fibrin and tissue plasminogen activator. Bioconjug Chem 1: 274–277CrossRefGoogle Scholar
  20. 20.
    Branscomb EE, Runge MS, Savard CE. Adams KM, Matsueda GR. Haber E (1990) Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Thromb Haemost 64: 260–266Google Scholar
  21. 21.
    Goldstein J, Matsueda GR, Shaw S-Y (1996) A chimenic streptokinase with unexpected fibrinolytic selectivity. Thromb Haemost 76: 429–438Google Scholar
  22. 22.
    Schnee JM, Runge MS. Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T (1987) Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 84: 6904–6908CrossRefGoogle Scholar
  23. 23.
    Love TW, Quertermous T, Runge MS, Michelson KD, Matsueda GR, Haber E (1994) Attachment of an antifibrin antibody to the amino terminus of tissue-type plasminogen activator impairs stimulation by fibrin. Fibrinolysis 8: 326–332Google Scholar
  24. 24.
    Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C. Freitag M, Shaw S-Y, Huang PL. Chou C-C, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR. Haber E (1991) A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Nat Acad Sci USA 88: 10337–10341CrossRefGoogle Scholar
  25. 25.
    Runge MS, Harker LA, Bode C, Ruef J, Kelly AB. Marzec UM; Allen E. Caban R, Shaw S-Y, Haber E. Hanson SR (1996) Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 94:14121–422CrossRefGoogle Scholar
  26. 26.
    Peter K, Tovic I, Graeber J, Weirich U, Bauer S, Ruef J, Nordt T, Bode C (2001) Construction and functional evaluation of a new fibrin-targeted fibrinolytic: a recombinant fusion protein with an anti-fibrin single-chain antibody and a low molecular weight form single-chain urokinase. Circulation 104:SII-96Google Scholar
  27. 27.
    Dewerchin M, Vandamme AM. Holvoet P, De Cock F, Lemmens G. Lijnen HR. Stassen JM. Gollen D (1992) Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Thromb Haemost 68:170–179Google Scholar
  28. 28.
    Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D (1993) Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood 81: 696–703Google Scholar
  29. 29.
    Yang W-P. Goldstein J, Procyk R, Matsueda GR. Shaw S-Y (1994) Design and evaluation of a thrombin-activable plasminogen activator. Biochemistry 33: 2306–2312Google Scholar
  30. 30.
    Yamada T, Shimada Y. Kikuchi M (1996) Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Biochem Biophys Res Commun 228: 306–311CrossRefGoogle Scholar
  31. 31.
    Dawson KM, Cook A, Devine JM. Edwards RM, Hunter MG. Raper RH. Roberts G (1994) Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. J Biol Chem 269: 15989–15992Google Scholar
  32. 32.
    Wan H, Liu Z. Xia X, Gu J, Wang B. Liu X. Zhu M. Li P, Ruan C (2000) A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo. Thromb Res 97: 133–141CrossRefGoogle Scholar
  33. 33.
    Hua Z-C, Chen X-C, Dong C, Zhu D-X (1996) Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli. Biochem Biophys Res Commun 222: 576–583CrossRefGoogle Scholar
  34. 34.
    Tait JF, Engelhardt S, Smith C, Fujikawa K (1995) Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins. J Biol Chem 270: 21594–21599CrossRefGoogle Scholar
  35. 35.
    van Zvl WB. Pretorius GHJ. Hartmann M. Kotze HF (1997) Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. Thromb Res88: 419–426CrossRefGoogle Scholar
  36. 36.
    Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E. Newell JB, Kübler W, Haber E, Runge MS (1994) Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 90: 1956–1963CrossRefGoogle Scholar
  37. 37.
    Bode C, Hanson SR, Schmedtje JF Jr. Haber E, Mehwald P, Kelly AB. Harker LA, Runge MS (1997) Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation 95:800–804CrossRefGoogle Scholar
  38. 38.
    Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kibler W, Little M, Bode C (2000) Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 101: 1158–1164CrossRefGoogle Scholar
  39. 39.
    Muzykantov VR, Barnathan ES, Atochina EN, Kuo A, Danilov SM, Fisher AB (1996) Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. J Pharmacol Exp Ther 279: 1026–1034Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Karlheinz Peter
    • 1
  • Christoph Bode
    • 1
  1. 1.Department of Cardiology and AngiologyUniversity of FreiburgFreiburgGermany

Personalised recommendations